Search results for "CAG"

showing 10 items of 492 documents

Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome.

2020

Stiff person syndrome (SPS) is a rare neurologic disorder characterized by progressively worsening rigidity and spasms of the axial and limb muscles. Dyspnea has been recently recognized as a common symptom in SPS,1 and life-threatening respiratory crises have been occasionally reported and suspected to be responsible for sudden death in these patients.2,3 The pathophysiologic mechanisms of these respiratory manifestations remain unclear. Some authors have hypothesized that rigidity and/or spasm of the muscles of the trunk could prevent normal rib cage movements and excursion of the diaphragm.1

131040301 veterinary sciencesMidazolam116Stiff-Person Syndromerespiratory crisesSudden deathstiff person syndrome midazolam respiratory crises0403 veterinary science03 medical and health sciencesBenzodiazepines0302 clinical medicineMedicineHumansStiff syndromeRespiratory systemIntranasal midazolamintranasal midazolamClinical/Scientific NotesAdministration IntranasalRib cagebusiness.industry30304 agricultural and veterinary sciencesMiddle Agedmedicine.diseaseTrunkbody regionsDyspneaNeurologyAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessRespiratory Insufficiency030217 neurology & neurosurgeryStiff person syndromeNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patie…

2014

Introduction Particularly in the setting of acute coronary syndromes, the interplay between vascular and platelet function has been postulated to have direct clinical implications. The present trial is designed to test the effect of clopidogrel, prasugrel and ticagrelor on multiple parameters of vascular function, platelet aggregation, oxidative and inflammatory stress before and up to 4 weeks after coronary artery stenting. Methods and analysis The study is designed as a three-arm, parallel design, randomised, investigator-blinded study. Patients with unstable angina or non-ST elevation myocardial infarction undergoing coronary intervention with a drug-eluting stent will be randomised to r…

1683AdultBlood PlateletsMaleTicagrelorAdenosineTiclopidineAdolescent610 MedizinCardiovascular MedicineYoung AdultPercutaneous Coronary Intervention610 Medical sciencesProtocolHumansSingle-Blind Method1506Prospective StudiesAcute Coronary Syndrome1707AgedDrug-Eluting StentsMiddle AgedClopidogrelOxidative StressTreatment OutcomePurinergic P2Y Receptor AntagonistsFemaleEndothelium VascularPrasugrel HydrochloridePlatelet Aggregation InhibitorsFollow-Up Studies
researchProduct

Microdiversity of Burkholderiales associated with mycorrhizal and nonmycorrhizal roots of Medicago truncatula

2008

The genetic diversity of bacterial communities associated with mycorrhizal and nonmycorrhizal roots of Medicago truncatula was characterized by two approaches. Firstly, phylogenetic analysis was performed on 164 partial 16S rRNA gene-intergenic spacer (IGS) sequences from operational taxonomic units previously shown to be preferentially associated with mycorrhizal roots. These sequences were distributed into three branches corresponding to Comamonadaceae, Oxalobacteraceae and Rubrivivax subgroups. Most sequences were obtained from mycorrhizal roots, indicating the preferential association of the corresponding families with mycorrhizal roots. A second phylogenetic analysis was performed on t…

2. Zero hunger0303 health sciencesRhizosphereMedicagoEcologybiology030306 microbiologyContext (language use)15. Life on landbiology.organism_classificationApplied Microbiology and BiotechnologyMicrobiologyMedicago truncatulaComamonadaceae03 medical and health sciencesBurkholderialesBotanyMycorrhiza030304 developmental biologyOxalobacteraceaeFEMS Microbiology Ecology
researchProduct

TheMedicago truncatulahypermycorrhizal B9 mutant displays an altered response to phosphate and is more susceptible toAphanomyces euteiches

2014

Inorganic phosphate (Pi) plays a key role in the development of arbuscular mycorrhizal (AM) symbiosis, which is favoured when Pi is limiting in the environment. We have characterized the Medicago truncatula hypermycorrhizal B9 mutant for its response to limiting (P/10) and replete (P2) Pi. On P2, mycorrhization was significantly higher in B9 plants than in wild-type (WT). The B9 mutant displayed hallmarks of Pi-limited plants, including higher levels of anthocyanins and lower concentrations of Pi in shoots than WT plants. Transcriptome analyses of roots of WT and B9 plants cultivated on P2 or on P/10 confirmed the Pi-limited profile of the mutant on P2 and highlighted its altered response t…

2. Zero hungerOomycetebiologyPhysiologyfungiMutantfood and beveragesPlant Sciencebiology.organism_classificationMedicago truncatulaMicrobiologyTranscriptomeArbuscular mycorrhizaSymbiosisBotanyShootAphanomyces euteichesPlant, Cell & Environment
researchProduct

Endohedral Mixed Aggregates: Sodium Alkoxide Cages with Organic or Inorganic Central Anions and Variable Hull.

2021

Abstract Alkali metal alkoxides are widely used in chemistry due to their Brønsted basic and nucleophilic properties. Potassium alkoxides assist alkyllithium in the metalation of hydrocarbons in Lochmann‐Schlosser‐bases. Both compounds form mixed aggregates, which enhance the thermal stability, solubility, and the basic reactivity of these mixtures. A very unusual spherical mixed alkoxy aggregate was discovered by Grützmacher et al., where a central dihydrogen phosphide anion is surrounded by a highly dynamic shell of thirteen sodium atoms and a hull of twelve tert‐butoxide groups. This structural motif can be reproduced by a reaction of trimethylsilyl compounds of methane, halogens, or pse…

540 Chemistry and allied sciencesMetalationSodiumalkoxidechemistry.chemical_elementHot Paper010402 general chemistry01 natural sciencesCatalysischemistry.chemical_compoundPolymer chemistryNucleophilic substitutionReactivity (chemistry)isotopic labelingsodiumFull Paper010405 organic chemistryOrganic ChemistryaggregationGeneral ChemistryFull PapersAlkali metal0104 chemical scienceschemistry540 ChemieAlkoxideHalogenAlkoxy groupcage compoundsChemistry (Weinheim an der Bergstrasse, Germany)
researchProduct

A subset of flavaglines inhibits KRAS nanoclustering and activation.

2020

The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loading and oncogene activation in cells at nanomolar concentrations. Treatment with rocaglamide, the first discovered flavagline, inhibited the nanoclustering of KRAS, but not HRAS and NRAS, at specific phospholipid-enriched plasma membrane domains. We further demonstrate that plasma membrane-associated prohibitins directly interact with KRAS, phosphatidylserine and phosphatidic acid, and these int…

:Bioengineering [Engineering]Neuroblastoma RAS viral oncogene homologGene isoformLung NeoplasmsGTP'[SDV]Life Sciences [q-bio]AucunBiology: Biochemistry biophysics & molecular biology [F05] [Life sciences]medicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRocaglamideCarcinoma Non-Small-Cell LungmedicineKRASHumansdrug therapy;geneticsgeneticsHRASProhibitin: Biochimie biophysique & biologie moléculaire [F05] [Sciences du vivant]neoplasmsComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesOncogeneLipid nanoclusterOncogenesCell Biologydigestive system diseases3. Good healthrespiratory tract diseasesPhospholipidchemistry030220 oncology & carcinogenesisMutationCancer researchKRASFlavaglineRocaglamideProhibitinSignal Transduction
researchProduct

Between Interactions and Aggregates: The PolyQ Balance

2021

Abstract Polyglutamine regions (polyQ) are highly abundant consecutive runs of glutamine residues. They have been generally studied in relation to the so-called polyQ-associated diseases, characterized by protein aggregation caused by the expansion of the polyglutamine tract via a CAG-slippage mechanism. However, more than 4800 human proteins contain a polyQ, and only 9 of these regions are known to be associated with disease. Computational sequence studies and experimental structure determinations are completing a more interesting picture in which polyQ emerge as a motif for modulation of protein-protein interactions. But long polyQ regions may lead to an excess of interactions, and produc…

AcademicSubjects/SCI01140AcademicSubjects/SCI01130aggregationCAG-expansion diseasesContext (language use)Computational biologyReviewPolyglutamine tractBiologyProtein aggregationProtein–protein interactionhomorepeatprotein–protein interactionCodon usage biasGeneticsHumansPeptidesHuman proteinspolyglutamineEcology Evolution Behavior and SystematicsFunction (biology)Sequence (medicine)Genome Biology and Evolution
researchProduct

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, p…

2021

The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment (DAPT). Several de-escalation strategies of antiplatelet treatment aiming to enhance safety of DAPT without depriving it of its efficacy have been evaluated so far. We hypothesized that reduction of the ticagrelor maintenance dose 1 month after ACS and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticagrelor. Moreover, improved safety of treatment and preserved anti-is…

Acute coronary syndromemedicine.medical_specialtyELECTRA-SIRIO 2TicagrelorClinical CardiologyPlaceboantiplatelet therapylaw.inventionacute coronary syndrometicagrelorClinical studyPercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineHumansAcute Coronary SyndromeAspirinbusiness.industryMaintenance doseGeneral Medicinemedicine.diseasede-escalationTolerabilityELECTRA-SIRIO 2 ; acute coronary syndrome ; antiplatelet therapy ; de-escalation ; ticagrelorCardiologyCardiology and Cardiovascular MedicinebusinessTicagrelorDe-escalationPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

2014

Introduction Particularly in the setting of acute coronary syndromes, the interplay between vascular and platelet function has been postulated to have direct clinical implications. The present trial is designed to test the effect of clopidogrel, prasugrel and ticagrelor on multiple parameters of vascular function, platelet aggregation, oxidative and inflammatory stress before and up to 4 weeks after coronary artery stenting. Methods and analysis The study is designed as a three-arm, parallel design, randomised, investigator-blinded study. Patients with unstable angina or non-ST elevation myocardial infarction undergoing coronary intervention with a drug-eluting stent will be randomised to r…

Acute coronary syndromemedicine.medical_specialtyPrasugrel HydrochloridePrasugrelUnstable anginabusiness.industryGeneral MedicineClopidogrelmedicine.diseaseInternal medicinemedicineCardiologyPlatelet aggregation inhibitorTiclopidinebusinessTicagrelormedicine.drugBMJ Open
researchProduct

Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study

2020

Objective To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). Methods A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV. Results Thirteen patients were included. During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98 …

AdultBlood GlucoseMaleAcute coronary syndromemedicine.medical_specialtyProspective Clinical Research ReportMedicine (General)Hospital settingtype 2 diabetes mellitusGLP-1 receptor agonistInsulin Glargine030209 endocrinology & metabolismPilot Projects030204 cardiovascular system & hematologyHypoglycemiaBiochemistryacute coronary syndrome03 medical and health sciencesRandom Allocation0302 clinical medicineR5-920Internal medicineMedicineHumansHypoglycemic AgentsInsulinGlycemic variabilityGlucagon-like peptide 1 receptorGlycemicGlycated Hemoglobinliraglutidebusiness.industryInsulin glargineLiraglutideBiochemistry (medical)Type 2 Diabetes MellitusCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseHypoglycemiaMetforminDiabetes Mellitus Type 2Glycemic IndexSpainFemalebusinessmedicine.drugJournal of International Medical Research
researchProduct